PEPTIDESTAT
ApprovedWeight lossSubcutaneousEvidence 4/5

Lixisenatide

Also known as: Adlyxin, Lyxumia

Lixisenatide is an exendin-4-derived GLP-1 receptor agonist that slows gastric emptying and lowers postprandial glucose while stimulating glucose-dependent insulin release and suppressing glucagon.

Read guideBuy / compare source
Lixisenatide
Drug class
Short-acting (prandial) GLP-1 receptor agonist; exendin-4-derived peptide
Primary targets
GLP-1 receptor (GLP-1R)
Dose reference
Reference (Adlyxin label, not a recommendation): 10 mcg once daily subcutaneously for 14 days, then 20 mcg once daily maintenance, injected within one hour before the first meal.
Half-life
Approximately 3 hours (reported range ~2.7-4.3 hours)
Developer / origin
Discovered by Zealand Pharma; developed and marketed by Sanofi (Sanofi-Aventis)
Reference year
2016
Evidence score
4/5 - Approved drug with neutral cardiovascular outcomes; modest glycemic, not weight-loss, indication
Evidence 4/5

Approved drug with neutral cardiovascular outcomes; modest glycemic, not weight-loss, indication

Lixisenatide is FDA- and EMA-approved for type 2 diabetes based on the GetGoal phase 3 program, with the ELIXA cardiovascular outcomes trial establishing cardiovascular safety (non-inferiority) but not benefit. It was not approved as a weight-loss drug, and the standalone US product was discontinued in 2023.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • FDA Adlyxin prescribing information (initial U.S. approval July 27, 2016)
  • ELIXA randomized trial of 6,068 patients (NEJM 2015;373:2247-2257): primary CV composite 13.4% lixisenatide vs 13.2% placebo, non-inferior, not superior, heart-failure neutral
  • GetGoal phase 3 program: modest HbA1c reduction with predominant postprandial glucose effect
  • Pharmacology: exendin-4-derived 44-amino-acid peptide, ~3 hour half-life, once-daily prandial dosing

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Lixisenatide guides

Read the matching guide or adjacent research pages for more context.

Lixisenatide Peptide: Adlyxin, Lyxumia, ELIXA and Safety LimitsLixisenatide is a short-acting exendin-based GLP-1 receptor agonist approved for type 2 diabetes, with neutral cardiovascular data and clear safety limits.Every GLP-1 Drug Approved in 2026 (Plus the Pipeline)Seven GLP-1 receptor agonists carry FDA approval in 2026 across diabetes and weight-management labels, with a deep pipeline behind them — brand names, doses and approval years for each.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.GLP-1 for Weight Loss: How Well They Work, and What They CostGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.